Lead Product(s) : BMX-101
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Onward Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Biomunex and Onward will jointly develop, in a preclinical and early clinical program (BMX-101), a ‘first-in-class’ immunotherapeutic bispecific antibody, in hematological malignancies, developed by bi- and multi-specific antibody platform BiXAb.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 16, 2021
Lead Product(s) : BMX-101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Onward Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
